106 related articles for article (PubMed ID: 21403611)
1. Interaction between tumor and immune system: the role of tumor cell biology.
Berezhnaya NM
Exp Oncol; 2010 Sep; 32(3):159-66. PubMed ID: 21403611
[TBL] [Abstract][Full Text] [Related]
2. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin.
Berezhnaya NM; Vinnichuk YD; Belova OB
Exp Oncol; 2008 Mar; 30(1):52-5. PubMed ID: 18438341
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
4. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
5. [Accomplishments and perspectives in tumor diagnostics and treatment].
Spuzić I
Glas Srp Akad Nauka Med; 2002; (47):21-32. PubMed ID: 16078439
[TBL] [Abstract][Full Text] [Related]
6. Human natural killer cells: a comprehensive review.
Sinkovics JG; Horvath JC
Int J Oncol; 2005 Jul; 27(1):5-47. PubMed ID: 15942642
[TBL] [Abstract][Full Text] [Related]
7. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
9. Expression of E-cadherin in drug resistant human breast cancer cells and their sensitivity to lymphokine-activated lymphocytes action.
Berezhnaya NM; Belova OB; Vinnichuk YD; Tarutinov VI
Exp Oncol; 2009 Dec; 31(4):242-5. PubMed ID: 20010527
[TBL] [Abstract][Full Text] [Related]
10. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 2-activated cytotoxic lymphocytes in cancer therapy.
Grimm EA; Jacobs SK; Lanza LA; Melin G; Roth JA; Wilson DJ
Symp Fundam Cancer Res; 1986; 38():209-19. PubMed ID: 3489259
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of different immunotherapy approaches toward treatment of doxorubicin-resistant and doxorubicin-sensitive transplantable rhabdomyosarcoma.
Belova OB; Vinnichuk UD; Shlakhovenko VA; Berezhnaya NM
Exp Oncol; 2007 Dec; 29(4):272-6. PubMed ID: 18199982
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
14. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?
Hamaï A; Benlalam H; Meslin F; Hasmim M; Carré T; Akalay I; Janji B; Berchem G; Noman MZ; Chouaib S
Tissue Antigens; 2010 Jan; 75(1):1-8. PubMed ID: 20196816
[TBL] [Abstract][Full Text] [Related]
15. An outsider's perspective--ecotaxis revisited: an integrative review of cancer environment, iron and immune system cells.
de Sousa M
Integr Biol (Camb); 2011 Apr; 3(4):343-9. PubMed ID: 21180734
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
17. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
19. The role of tumor stroma in the interaction between tumor and immune system.
Blankenstein T
Curr Opin Immunol; 2005 Apr; 17(2):180-6. PubMed ID: 15766679
[TBL] [Abstract][Full Text] [Related]
20. Gene transfer approaches in cancer immunotherapy.
Larin SS; Georgiev GP; Kiselev SL
Gene Ther; 2004 Oct; 11 Suppl 1():S18-25. PubMed ID: 15454953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
